Tags

Type your tag names separated by a space and hit enter

Maxingshigan decoction for treating COVID-19: A protocol for systematic review and meta analysis.
Medicine (Baltimore). 2020 Nov 25; 99(48):e23224.M

Abstract

BACKGROUND

Coronavirus disease 2019 (COVID-19) is a rapidly spreading disease that has been in a public health emergency of international concern since its outbreak in 2020. Due to the complex pathogenesis and susceptibility of COVID-19, many commonly used drugs for the treatment of COVID-19 have not shown excellent clinical effects. Traditional Chinese medicine has a long clinical history of preventing and treating this respiratory infectious disease. Maxingshigan Decoction (MXSG) is widely used in China to treat COVID-19. However, there is no comprehensive and systematic evidence on the effectiveness and safety of Maxingshigan Decoction.

METHODS

PubMed, EMBASE, Clinical Trials, the Cochrane Library, Sino Med, and China National Knowledge Infrastructure up to September 2020. This study only screens clinical randomized controlled trials on MXSG for COVID-19 to evaluate its efficacy and safety. Data were extracted by 1 investigator and checked by an independent investigator. Review Manager 5.3 software was used for the data analysis. The dichotomous data is represented by relative risk, and the continuous is expressed by mean difference or standard mean difference, eventually the data is synthesized using a fixed effect model or a random effect model depending on whether or not heterogeneity exists.

RESULTS

The time from a positive diagnosis to a negative result of 2 consecutive nucleic acid tests (not on the same day), cure rate. The results of our research will be published in a peer-reviewed journal.

CONCLUSION

The purpose of this systematic review is to provide new evidence for the effectiveness and safety of Maxingshigan decoction in the treatment of COVID-19.

PROSPERO REGISTRATION NUMBER

CRD42020211962.

Authors+Show Affiliations

Acupuncture and Tuina College, Shandong University of Traditional Chinese Medicine.Acupuncture and Tuina College, Shandong University of Traditional Chinese Medicine.Master of Clinical Integration in Traditional Chinese and Western Medicine, College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine.Acupuncture and Tuina College, Shandong University of Traditional Chinese Medicine. Department of Acupuncture, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China.

Pub Type(s)

Journal Article
Meta-Analysis
Systematic Review

Language

eng

PubMed ID

33235080

Citation

Shao, Guoliang, et al. "Maxingshigan Decoction for Treating COVID-19: a Protocol for Systematic Review and Meta Analysis." Medicine, vol. 99, no. 48, 2020, pp. e23224.
Shao G, Huang S, Cui Y, et al. Maxingshigan decoction for treating COVID-19: A protocol for systematic review and meta analysis. Medicine (Baltimore). 2020;99(48):e23224.
Shao, G., Huang, S., Cui, Y., & Yang, D. (2020). Maxingshigan decoction for treating COVID-19: A protocol for systematic review and meta analysis. Medicine, 99(48), e23224. https://doi.org/10.1097/MD.0000000000023224
Shao G, et al. Maxingshigan Decoction for Treating COVID-19: a Protocol for Systematic Review and Meta Analysis. Medicine (Baltimore). 2020 Nov 25;99(48):e23224. PubMed PMID: 33235080.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Maxingshigan decoction for treating COVID-19: A protocol for systematic review and meta analysis. AU - Shao,Guoliang, AU - Huang,Shaolei, AU - Cui,Yuying, AU - Yang,Dianhui, PY - 2020/11/25/entrez PY - 2020/11/26/pubmed PY - 2020/11/26/medline SP - e23224 EP - e23224 JF - Medicine JO - Medicine (Baltimore) VL - 99 IS - 48 N2 - BACKGROUND: Coronavirus disease 2019 (COVID-19) is a rapidly spreading disease that has been in a public health emergency of international concern since its outbreak in 2020. Due to the complex pathogenesis and susceptibility of COVID-19, many commonly used drugs for the treatment of COVID-19 have not shown excellent clinical effects. Traditional Chinese medicine has a long clinical history of preventing and treating this respiratory infectious disease. Maxingshigan Decoction (MXSG) is widely used in China to treat COVID-19. However, there is no comprehensive and systematic evidence on the effectiveness and safety of Maxingshigan Decoction. METHODS: PubMed, EMBASE, Clinical Trials, the Cochrane Library, Sino Med, and China National Knowledge Infrastructure up to September 2020. This study only screens clinical randomized controlled trials on MXSG for COVID-19 to evaluate its efficacy and safety. Data were extracted by 1 investigator and checked by an independent investigator. Review Manager 5.3 software was used for the data analysis. The dichotomous data is represented by relative risk, and the continuous is expressed by mean difference or standard mean difference, eventually the data is synthesized using a fixed effect model or a random effect model depending on whether or not heterogeneity exists. RESULTS: The time from a positive diagnosis to a negative result of 2 consecutive nucleic acid tests (not on the same day), cure rate. The results of our research will be published in a peer-reviewed journal. CONCLUSION: The purpose of this systematic review is to provide new evidence for the effectiveness and safety of Maxingshigan decoction in the treatment of COVID-19. PROSPERO REGISTRATION NUMBER: CRD42020211962. SN - 1536-5964 UR - https://www.unboundmedicine.com/medline/citation/33235080/Maxingshigan_decoction_for_treating_COVID_19:_A_protocol_for_systematic_review_and_meta_analysis_ L2 - https://doi.org/10.1097/MD.0000000000023224 DB - PRIME DP - Unbound Medicine ER -